134 related articles for article (PubMed ID: 20530436)
1. A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Dugan E; Truax R; Meadows KL; Nixon AB; Petros WP; Favaro J; Fernando NH; Morse MA; Blobe GC; Hurwitz HI
Anticancer Res; 2010 Apr; 30(4):1251-6. PubMed ID: 20530436
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.
Mayr M; Becker K; Schulte N; Belle S; Hofheinz R; Krause A; Schmid RM; Röcken C; Ebert MP
BMC Cancer; 2012 Dec; 12():587. PubMed ID: 23228190
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
Halperin DM; Phan AT; Hoff AO; Aaron M; Yao JC; Hoff PM
BMC Cancer; 2014 Aug; 14():561. PubMed ID: 25086465
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
Chew HK; Barlow WE; Albain K; Lew D; Gown A; Hayes DF; Gralow J; Hortobagyi GN; Livingston R
Clin Breast Cancer; 2008 Dec; 8(6):511-5. PubMed ID: 19073506
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.
Hoehler T; von Wichert G; Schimanski C; Kanzler S; Moehler MH; Hinke A; Seufferlein T; Siebler J; Hochhaus A; Arnold D; Hallek M; Hofheinz R; Hacker UT
Br J Cancer; 2013 Sep; 109(6):1408-13. PubMed ID: 23963139
[TBL] [Abstract][Full Text] [Related]
6. A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Pishvaian MJ; Slack R; Koh EY; Beumer JH; Hartley ML; Cotarla I; Deeken J; He AR; Hwang J; Malik S; Firozvi K; Liu M; Elston B; Strychor S; Egorin MJ; Marshall JL
Cancer Chemother Pharmacol; 2012 Dec; 70(6):843-53. PubMed ID: 23014737
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
Díaz-Rubio E; Evans TR; Tabemero J; Cassidy J; Sastre J; Eatock M; Bisset D; Regueiro P; Baselga J
Ann Oncol; 2002 Apr; 13(4):558-65. PubMed ID: 12056706
[TBL] [Abstract][Full Text] [Related]
9. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.
Ali Y; Lin Y; Gharibo MM; Gounder MK; Stein MN; Lagattuta TF; Egorin MJ; Rubin EH; Poplin EA
Clin Cancer Res; 2007 Oct; 13(19):5876-82. PubMed ID: 17908982
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
Al-Batran SE; Atmaca A; Schleyer E; Pauligk C; Hosius C; Ehninger G; Jäger E
Cancer; 2007 May; 109(9):1897-904. PubMed ID: 17377918
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
Kellokumpu-Lehtinen PL; Sunela K; Lehtinen I; Joensuu H; Sjöström-Mattson J;
Clin Breast Cancer; 2006 Dec; 7(5):401-5. PubMed ID: 17239265
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
[TBL] [Abstract][Full Text] [Related]
20. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S
Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]